362691-33-6

Basic information

• Product Name: (S)-4-(5-{[(2-tert-butyldimethylsilyloxyethyl)[1-(3-chlorobenzyl)-2-oxopyrrolidin-3-yl]amino]methyl}imidazol-1-ylmethyl)benzonitrile
• Synonyms: (S)-4-(5-{[(2-tert-butyldimethylsilyloxyethyl)[1-(3-chlorobenzyl)-2-oxopyrrolidin-3-yl]amino]methyl}imidazol-1-ylmethyl)benzonitrile
• CAS NO: 362691-33-6
• Molecular Weight: 578.229
• Mol File: 362691-33-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (S)-4-(5-{[(2-tert-butyldimethylsilyloxyethyl)[1-(3-chlorobenzyl)-2-oxopyrrolidin-3-yl]amino]methyl}imidazol-1-ylmethyl)benzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-4-(5-{[(2-tert-butyldimethylsilyloxyethyl)[1-(3-chlorobenzyl)-2-oxopyrrolidin-3-yl]amino]methyl}imidazol-1-ylmethyl)benzonitrile(362691-33-6)
• EPA Substance Registry System: (S)-4-(5-{[(2-tert-butyldimethylsilyloxyethyl)[1-(3-chlorobenzyl)-2-oxopyrrolidin-3-yl]amino]methyl}imidazol-1-ylmethyl)benzonitrile(362691-33-6)

Safety Data

• Hazardous Substances Data: 362691-33-6(Hazardous Substances Data)

Upstream product

• 183500-37-0 4-[(5-formyl-1H-imidazol-1-yl)methyl]benzonitrile 
• 102191-92-4 tert-butyldimethylsiloxyacetaldehyde 
• 330185-25-6 MSD-1 

Downstream Products

• 330186-81-7 4-(2-{[1-(3-chloro-benzyl)-2-oxo-pyrrolidin-3-yl]-[3-(4-cyano-benzyl)-3H-imidazol-4-ylmethyl]-amino}-ethyl)-piperazine-1-carboxylic acid tert-butyl ester 
• 330186-80-6 (S)-2-{[1-(3-chlorobenzyl)-2-oxopyrrolidin-3-yl][3-(4-cyanobenzyl)imidazol-4-ylmethyl]amino}ethanal 

Relevant articles and documents

Design and biological activity of (S)-4-(5-{[1-(3-Chlorobenzyl)-2-oxopyrrolidin-3-ylamino]methyl}imidazol-1- ylmethyl)benzonitrile, a 3-aminopyrrolidinone farnesyltransferase inhibitor with excellent cell potency

The synthesis, structure-activity relationships, and biological properties of a novel series of imidazole-containing inhibitors of farnesyltransferase are described. Starting from a 3-amino-pyrrolidinone core, a systematic series of modifications provided 5h, a non-thiol, non-peptide farnesyltransferase inhibitor with excellent bioavailability in dogs. Compound 5h was found to have an unusually favorable ratio of cell potency to intrinsic potency, compared with other known FTIs. It exhibited excellent potency against a range of tumor cell lines in vitro and showed full efficacy in the K-rasB transgenic mouse model.